ORIGINAL RESEARCH ARTICLE

The Role of Probiotics in Preventing Antibiotic-Associated Diarrhea in Adult Patients: A Microbiological Perspective

Sarita[1], Bechan Kumar Gautam[2], Shubhankit Arya[3], Akanksha Chaudhary[4*]

[1,4]Assistant Professor, Microbiology, Baba Raghav Das Medical College Gorakhpur Uttar Pradesh

[2,3] Assistant Professor, Medicine, Baba Raghav Das Medical College Gorakhpur Uttar Pradesh

***Corresponding Author**: Akanksha Chaudhary, Assistant Professor, Microbiology, Baba Raghav Das Medical College, Gorakhpur, Uttar Pradesh, anjali1215@gmail.com*

Abstract

Background: Antibiotic-associated diarrhea (AAD) is a prevalent adverse effect of antibiotic therapy, disrupting the gut microbiota and leading to gastrointestinal complications. Probiotics have been suggested as a preventive measure against AAD, but comprehensive clinical trials are needed to confirm their efficacy and elucidate the underlying microbiological mechanisms.

Objective: This study aimed to evaluate the efficacy of a multi-strain probiotic formulation in preventing AAD in adult patients undergoing antibiotic therapy, focusing on the impact on gut microbiota composition and immune response.

Methods: A double-blind, placebo-controlled randomized trial was conducted over 12 months in a tertiary care hospital in North India. Two hundred adult patients receiving antibiotic therapy were randomly assigned to receive either a multi-strain probiotic formulation (Lactobacillus rhamnosus GG, Bifidobacterium lactis, and Saccharomyces boulardii) or a placebo. The primary outcome was the incidence of AAD during and up to 4 weeks' post-antibiotic therapy. Secondary outcomes included changes in gut microbiota composition, assessed through 16S rRNA sequencing, and immune response, measured by fecal IgA and cytokine levels. Stool samples were collected at baseline, end of therapy, and 4 weeks' post-therapy. Statistical analysis compared incidence rates, microbiota changes, and immune markers between groups.

Results: The probiotic group exhibited a significantly lower incidence of AAD (15%) compared to the placebo group (35%) ($p < 0.05$). The probiotic group also maintained higher levels of beneficial bacteria (Lactobacillus and Bifidobacterium) and lower levels of pathogenic bacteria (Clostridioides difficile). Immune response markers indicated a significant increase in fecal IgA levels and a favorable cytokine profile (IL-10 and TNF-α) in the probiotic group compared to the placebo group.

Discussion: The findings demonstrate that multi-strain probiotics significantly reduce the incidence of AAD by preserving gut microbiota balance and enhancing immune function. This study supports existing literature, such as McFarland (2006) and Snydman (2008), and provides detailed microbiological and immunological insights into probiotic action. Our results align with other randomized controlled trials and highlight the importance of probiotics in clinical practice to prevent AAD.

Conclusion: Probiotics, particularly multi-strain formulations, are effective in preventing AAD by maintaining gut microbiota integrity and boosting immune responses. These findings advocate for the use of probiotics as a complementary therapy during antibiotic treatment to mitigate adverse gastrointestinal effects. Further research should explore personalized probiotic therapies based on individual microbiota profiles.

Keywords: Antibiotic-associated diarrhea, probiotics, gut microbiota, immune response, randomized controlled trial, Lactobacillus, Bifidobacterium, Saccharomyces boulardii

Introduction

Antibiotic therapy, although essential for combating bacterial infections, can lead to significant disruptions in the gut microbiota, resulting in antibiotic-associated diarrhea (AAD). AAD can range from mild, self-limiting episodes of diarrhea to severe colitis, especially when caused by Clostridioides difficile. The incidence of AAD varies but can affect up to 30% of patients on antibiotics. The pathophysiology of AAD involves the broad-spectrum activity of antibiotics, which not only target pathogenic bacteria but also reduce the populations of beneficial gut microbes, thereby destabilizing the gut environment and allowing opportunistic pathogens to thrive.

Probiotics, defined as live microorganisms that confer health benefits when administered in adequate amounts, have been proposed as a strategy to mitigate AAD. Various strains, including Lactobacillus, Bifidobacterium, and Saccharomyces, have shown potential in restoring gut microbiota balance, enhancing the gut barrier function, and modulating the immune response. Despite promising results from several studies, there remains a need for comprehensive clinical trials to solidify the role of probiotics in preventing AAD. This study aims to fill this gap by evaluating the efficacy of a multi-strain probiotic formulation in adult patients undergoing antibiotic therapy.

Materials and Methods

This double-blind, placebo-controlled randomized trial was conducted over a period of 12 months in a tertiary care hospital in North India. Adult patients (18-65 years) receiving antibiotic therapy for various bacterial infections were recruited from multiple healthcare centers. Participants included adults aged 18-65 years who were receiving antibiotic therapy for a minimum of 7 days and had no prior history of chronic gastrointestinal diseases. Exclusion criteria comprised immunocompromised individuals, pregnant or lactating women, and those with recent use of probiotics or prebiotics.

Participants were randomly assigned to two groups: the probiotic group and the placebo group. The probiotic group received a daily dose of a multi-strain probiotic formulation, including Lactobacillus rhamnosus GG, Bifidobacterium lactis, and Saccharomyces boulardii, while the placebo group received a daily dose of a placebo.

The primary outcome was the incidence of AAD during and up to 4 weeks post-antibiotic therapy. Secondary outcomes included changes in gut microbiota composition assessed through 16S rRNA sequencing , and immune response measured by levels of fecal IgA and cytokines.

Stool samples were collected at baseline, at the end of antibiotic therapy, and 4 weeks post-therapy. Clinical assessments and questionnaires were used to document incidences of diarrhea and other gastrointestinal symptoms. Statistical analysis was performed to compare the incidence of AAD, changes in microbiota composition, and immune response markers between the two groups.

Results

Participant Characteristics

A total of 200 patients were enrolled, with 100 in each group. Baseline characteristics were comparable between groups.

Characteristic	Probiotic Group (n=100)	Placebo Group (n=100)
Age (mean ± SD)	45.2 ± 12.4	44.8 ± 11.9
Gender (M/F)	48/52	50/50
Duration of Antibiotic Therapy (days)	10.2 ± 3.1	10.4 ± 3.2
Type of Antibiotics Used	Various (penicillins, cephalosporins, quinolones)	Various (penicillins, cephalosporins, quinolones)

Incidence of AAD

The incidence of AAD was significantly lower in the probiotic group (15%) compared to the placebo group (35%) ($p < 0.05$).

Outcome	Probiotic Group (n=100)	Placebo Group (n=100)	p-value
Incidence of AAD	15 (15%)	35 (35%)	< 0.05
Mean duration of AAD (days)	2.3 ± 1.1	4.7 ± 2.3	< 0.05

Gut Microbiota Composition

16S rRNA sequencing revealed that the probiotic group maintained higher levels of beneficial bacteria (Lactobacillus and Bifidobacterium) and lower levels of pathogenic bacteria (Clostridioides difficile) compared to the placebo group.

Bacterial Genus	Baseline (Probiotic/Placebo)	Post-Therapy (Probiotic/Placebo)	4 Weeks Post-Therapy (Probiotic/Placebo)
Lactobacillus	8.2% / 8.1%	10.5% / 5.3%	9.8% / 6.2%
Bifidobacterium	6.3% / 6.5%	9.1% / 4.0%	8.5% / 5.1%
Clostridioides difficile	0.5% / 0.6%	0.3% / 1.8%	0.4% / 1.5%

Immune Response

The probiotic group showed a significant increase in fecal IgA levels and a favorable cytokine profile, indicating enhanced immune function.

Immune Marker	Baseline (Probiotic/Placebo)	Post-Therapy (Probiotic/Placebo)	4 Weeks Post-Therapy (Probiotic/Placebo)
Fecal IgA (mg/g)	0.92 / 0.91	1.34 / 0.98	1.28 / 1.01
IL-10 (pg/mg)	45.2 / 44.8	58.7 / 47.3	55.6 / 46.1
TNF-α (pg/mg)	12.1 / 12.3	9.8 / 15.2	10.3 / 14.5

Discussion

The findings of this study demonstrate that the administration of probiotics can significantly reduce the incidence of AAD in adult patients undergoing antibiotic therapy. The probiotic group exhibited a notably lower incidence of AAD compared to the placebo group, suggesting a protective effect of the probiotics. This aligns with previous studies that have highlighted the efficacy of specific probiotic strains in preventing AAD.

One of the critical mechanisms by which probiotics prevent AAD is by maintaining a balanced gut microbiota. Our microbiota analysis showed that the probiotic group retained higher levels of beneficial bacteria, such as Lactobacillus and Bifidobacterium, even after antibiotic therapy. These bacteria are known for their role in enhancing gut barrier function, producing antimicrobial substances, and outcompeting pathogenic bacteria for resources and adhesion sites. The reduced levels of Clostridioides difficile in the probiotic group further underscore the effectiveness of probiotics in preventing pathogenic colonization.

The immune response data revealed that probiotics can modulate the host's immune system. The increase in fecal IgA and the favorable cytokine profile in the probiotic group indicate that probiotics not only restore microbiota balance but also enhance mucosal immunity. This immunomodulatory

effect is crucial in providing an additional layer of defense against opportunistic infections during antibiotic therapy.

Comparatively, our study supports the findings of other RCTs that have shown a reduction in AAD incidence with probiotic use. For instance, a meta-analysis by McFarland (2006) reported a significant decrease in AAD incidence among patients treated with probiotics. Similarly, a study by Snydman (2008) demonstrated that probiotics effectively prevented AAD and Clostridioides difficile infections Our study uniquely contributes to the understanding of the specific microbiological and immunological mechanisms involved. Unlike some studies that focus solely on clinical outcomes, we have provided a detailed analysis of the gut microbiota composition and immune markers, offering a comprehensive view of how probiotics exert their protective effects.

Conclusion

Probiotics, particularly multi-strain formulations, play a significant role in preventing AAD by preserving gut microbiota and enhancing the immune response. These findings support the use of probiotics as a complementary therapy during antibiotic treatment to mitigate the adverse effects on gut health. Future research should continue to explore the mechanistic aspects of probiotic action and the potential for personalized probiotic therapies based on individual microbiota profiles.

References

1. Sullivan, Å., & Nord, C. E. (2005). Probiotics and gastrointestinal diseases. *Journal of Internal Medicine*, 257(1), 78-92.
2. McFarland, L. V. (2006). Meta-analysis of probiotics for the prevention of antibiotic-associated diarrhea and the treatment of Clostridium difficile disease. *The American Journal of Gastroenterology*, 101(4), 812-822.
3. Guarner, F., & Malagelada, J. R. (2003). Gut flora in health and disease. *The Lancet*, 361(9356), 512-519.
4. Surawicz, C. M. (2003). Probiotics, antibiotics-associated diarrhoea and Clostridium difficile diarrhoea in humans. *Best Practice & Research Clinical Gastroenterology*, 17(5), 775-783.
5. Doron, S., & Gorbach, S. L. (2006). Probiotics: their role in the treatment and prevention of disease. *Expert Review of Anti-infective Therapy*, 4(2), 261-275.
6. Snydman, D. R. (2008). The safety of probiotics. *Clinical Infectious Diseases*, 46(Supplement_2), S104-S111.
7. Quigley, E. M., & Flourie, B. (2007). Probiotics and irritable bowel syndrome: a rationale for their use and an assessment of the evidence to date. *Neurogastroenterology & Motility*, 19(3), 166-172.
8. Ritchie, M. L., & Romanuk, T. N. (2012). A meta-analysis of probiotic efficacy for gastrointestinal diseases. *PLoS ONE*, 7(4), e34938.
9. Plaza-Diaz, J., Ruiz-Ojeda, F. J., Gil-Campos, M., & Gil, A. (2019). Mechanisms of action of probiotics. *Advances in Nutrition*, 10(suppl_1), S49-S66.
10. Hill, C., Guarner, F., Reid, G., Gibson, G. R., Merenstein, D. J., Pot, B., ... & Sanders, M. E. (2014). The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. *Nature Reviews Gastroenterology & Hepatology*, 11(8), 506-514.